Back to Insights

Accounting for inflation within NICE cost-effectiveness thresholds

Why are some drugs that may be demonstrated as cost-effective not being recommended for reimbursement? PRECISIONadvisors Richard Macaulay and his co-author have published this influential study, uncovering that the NICE ICER thresholds have declined by 42.9% in real terms since 2004 (without accounting for inflation).

Click here to learn more, or to access the complete study, contact Richard Macaulay at richard.macaulay@precisionvh.com 

2021-06-15T12:34:23-04:00